The iShares Genomics Immunology and Healthcare ETF (NYSE ARCA:IDNA) is an investment fund that primarily focuses on companies involved in genomics, immunology, and bioengineering. To achieve its investment objectives, the fund typically allocates at least 80% of its assets to securities that are part of its underlying index or to investments that closely mirror the characteristics of those securities.
The fund's underlying index is a collection of companies from both developed and emerging markets that are poised to benefit from advancements and growth in the fields of genomics, immunology, and bioengineering. These companies are likely to be involved in various activities such as gene editing, gene therapy, immunotherapy, and the development of new medical treatments and technologies.
In addition to investing in the securities of its underlying index, the fund may also allocate up to 20% of its assets to other investments such as futures contracts, options contracts, swap contracts, cash, and cash equivalents. These investments can provide the fund with additional flexibility and help it to manage its risk exposure.
By investing in the iShares Genomics Immunology and Healthcare ETF, investors can gain exposure to a diversified portfolio of companies that are at the forefront of innovation in the healthcare and biotechnology sectors. This can provide investors with the potential for long-term growth and returns, although it's essential to note that investing in the fund also involves risks and uncertainties.